Press Releases

(Shanghai, China, December 13, 2024) —WuXi XDC Cayman Inc. (“WuXi XDC”, or the “Company”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), is proud to announce that it has been awarded the “Most Valuable Pharmaceutical and Healthcare Company” and “Best CFO” at the 2024 Annual Leading CFO Awards for Hong Kong and U.S. listed companies. The awards were jointly organized by Zhitong Caijing, a leading domestic platform for Hong Kong and U.S. stock information, and Xinzhi Fund Network.

The “Most Valuable Pharmaceutical and Healthcare Company” award recognizes Hong Kong and U.S. listed companies in the healthcare sector that exhibit a healthy corporate governance structure, prominent industry position, sustainable business, and deliver long-lasting value for investors. The “Best CFO” award recognizes financial leaders who have demonstrated outstanding leadership and professionalism.

As the leading global end-to-end CRDMO service provider for bioconjugates, WuXi XDC is dedicated to propelling industry development, empowering customers, and creating social value. In 2024, WuXi XDC achieved robust financial results primarily driven by organic business growth, meticulous financial planning, and effective risk management. WuXi XDC is dedicated to delivering customer projects with exceptional speed and top-notch quality through continuous technological innovation. Riding on the fast-growing bioconjugate industry, WuXi XDC has achieved rapid market expansion and financial performance growth, consistently generating significant value for investors and the industry.

Mr. Michael Xi, Chief Financial Officer of WuXi XDC, commented, “In this fast-paced development stage of the biconjugate sector, WuXi XDC is committed to advancing and transforming the bioconjugate drug industry to benefit our global partners and patients worldwide ultimately. We firmly believe innovation is the key driver of forging ahead in the bioconjugate drug sector. Therefore, through continuous investment in research and development and capacity expansion, we will maintain our position at the forefront of innovation and provide the best bioconjugate CRDMO service. We will continue to drive sustainable business growth and maximize shareholder value.”

About WuXi XDC

WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.
 
WuXi XDC Contacts

Investor：wuxixdc.ir@wuxibiologics.com

Media：wuxixdc_pr@wuxibiologics.com

BD：wuxixdc_info@wuxibiologics.com